Regeneron Pharmaceuticals (REGN) Latest Stock Analysis Report – Oct 15, 2026, 4:00 PM ET
Updated Oct 15, 2026, 4:00 PM ET
REGN rises 2.3% to $796.34. Closed at $796.34, +2.31% vs the prior close of $778.36. Day range $792.58–$809.49, opened at $802.33.
REGN daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 15, 2026 — REGN rises 2.3% to $796.34
- Closed at $796.34, +2.31% vs the prior close of $778.36. Day range $792.58–$809.49, opened at $802.33.
- Volume was 798.80K shares, 1.1x its 50-day average of 708.85K.
- Price is +0.7% vs its 50-day average ($790.48) and +8.3% vs its 200-day average ($735.33).
- 52-week range $564.00–$859.34; today's close sits at 79% of that range, 7.3% below the 52-week high.
Oct 14, 2026 — REGN jumps 3.4% to $778.36
- Closed at $778.36, +3.35% vs the prior close of $753.12. Day range $755.21–$781.84, opened at $758.16.
- Volume was 878.40K shares, 1.2x its 50-day average of 707.63K.
- Price is -1.5% vs its 50-day average ($789.93) and +5.9% vs its 200-day average ($735.25).
- 52-week range $553.87–$859.34; today's close sits at 73% of that range, 9.4% below the 52-week high.
Oct 13, 2026 — REGN dips 1.3% to $753.12
- Closed at $753.12, -1.27% vs the prior close of $762.81. Day range $743.57–$765.60, opened at $762.49.
- Volume was 629.60K shares, 0.9x its 50-day average of 711.89K.
- Price is -4.6% vs its 50-day average ($789.57) and +2.4% vs its 200-day average ($735.29).
- 52-week range $541.00–$859.34; today's close sits at 67% of that range, 12.4% below the 52-week high.
Oct 12, 2026 — REGN rises 2.2% to $762.81
- Closed at $762.81, +2.18% vs the prior close of $746.54. Day range $744.96–$768.66, opened at $748.67.
- Volume was 618.20K shares, 0.9x its 50-day average of 722.69K.
- Price is -3.4% vs its 50-day average ($789.69) and +3.7% vs its 200-day average ($735.44).
- 52-week range $541.00–$859.34; today's close sits at 70% of that range, 11.2% below the 52-week high.
Oct 9, 2026 — REGN rises 0.9% to $746.54
- Closed at $746.54, +0.94% vs the prior close of $739.57. Day range $732.83–$751.27, opened at $737.20.
- Volume was 466.00K shares, 0.6x its 50-day average of 742.59K.
- Price is -5.5% vs its 50-day average ($789.69) and +1.5% vs its 200-day average ($735.55).
- 52-week range $541.00–$859.34; today's close sits at 65% of that range, 13.1% below the 52-week high.
Oct 8, 2026 — REGN dips 0.3% to $739.57
- Closed at $739.57, -0.34% vs the prior close of $742.12. Day range $723.65–$744.50, opened at $742.12.
- Volume was 500.30K shares, 0.7x its 50-day average of 753.02K.
- Price is -6.3% vs its 50-day average ($789.53) and +0.5% vs its 200-day average ($735.71).
- 52-week range $541.00–$859.34; today's close sits at 62% of that range, 13.9% below the 52-week high.
Oct 7, 2026 — REGN rises 0.5% to $742.12
- Closed at $742.12, +0.46% vs the prior close of $738.72. Day range $734.18–$753.68, opened at $738.05.
- Volume was 626.40K shares, 0.8x its 50-day average of 758.50K.
- Price is -5.9% vs its 50-day average ($788.64) and +0.9% vs its 200-day average ($735.86).
- 52-week range $541.00–$859.34; today's close sits at 63% of that range, 13.6% below the 52-week high.
Oct 6, 2026 — REGN rises 1.7% to $738.72
- Closed at $738.72, +1.69% vs the prior close of $726.47. Day range $727.16–$740.51, opened at $734.61.
- Volume was 615.10K shares, 0.8x its 50-day average of 759.21K.
- Price is -6.2% vs its 50-day average ($787.70) and +0.4% vs its 200-day average ($735.89).
- 52-week range $541.00–$859.34; today's close sits at 62% of that range, 14.0% below the 52-week high.
- SEC filings that day: 8-K.
- This was a results day: the company filed an earnings release (8-K Item 2.02).
Oct 5, 2026 — REGN dips 1.2% to $726.47, a 1-month low
- Closed at $726.47, -1.19% vs the prior close of $735.20. Day range $722.02–$736.42, opened at $734.37.
- Volume was 694.70K shares, 0.9x its 50-day average of 759.49K.
- Price is -7.6% vs its 50-day average ($786.27) and -1.3% vs its 200-day average ($735.94).
- 52-week range $541.00–$859.34; today's close sits at 58% of that range, 15.5% below the 52-week high.
Oct 2, 2026 — REGN ends flat (+0.1%) to $735.20
- Closed at $735.20, +0.05% vs the prior close of $734.81. Day range $729.20–$742.50, opened at $740.50.
- Volume was 613.90K shares, 0.8x its 50-day average of 769.80K.
- Price is -6.3% vs its 50-day average ($784.86) and -0.1% vs its 200-day average ($736.04).
- 52-week range $541.00–$859.34; today's close sits at 61% of that range, 14.4% below the 52-week high.
REGN latest news & SEC filings
Every SEC filing by or about REGN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 15, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Murphy Andrew J converted options/RSUs into 17,000 shares at $381.92 (≈$6.49M) on Oct 13, 2026; now holds 64,833
- Murphy Andrew J had withheld for taxes 12,853 shares at $754.58 (≈$9.70M) on Oct 13, 2026; now holds 51,980
- Murphy Andrew J sold 6 shares at $753.76 (≈$4.52K) on Oct 14, 2026; now holds 51,974
- Murphy Andrew J sold 35 shares at $755.91 (≈$26.46K) on Oct 14, 2026; now holds 51,939
- Murphy Andrew J sold 16 shares at $757.68 (≈$12.12K) on Oct 14, 2026; now holds 51,923
- Murphy Andrew J sold 24 shares at $758.16 (≈$18.20K) on Oct 14, 2026; now holds 51,899
- …plus 23 more transaction lines in the filing.
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 14, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Oct 6, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 2.02 — Reported results of operations (earnings release).
- Item 8.01 — Reported other events the company considers important.
This is a results-day filing: the earnings press release is attached as an exhibit.
Sep 30, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
Sep 3, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Mccourt Marion sold 1,131 shares at $857.39 (≈$969.71K) on Sep 3, 2026
- Mccourt Marion sold 1,215 shares at $850.00 (≈$1.03M) on Sep 2, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 3, 2026 · 4 — Insider trade report (Form 4)
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Guarini Kathryn sold 400 shares at $850.00 (≈$340.00K) on Sep 2, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 3, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 2, 2026 · 144 — Notice of proposed sale (Form 144)
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 20, 2026 · N-PX — Annual proxy voting record
Annual proxy voting record
Aug 7, 2026 · 13F-HR — Quarterly holdings report filed by an institutional investment manager
Quarterly holdings report filed by an institutional investment manager
Jul 30, 2026 · 10-Q — Quarterly report (unaudited financial statements for the quarter)
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $4.29B (prior year $3.68B) (+16.7% vs Jun 30, 2025)
- Net income: $1.30B (prior year $1.39B) (-6.8% vs Jun 30, 2025)
- Diluted EPS: $12.23 (prior year $12.81) (-4.5% vs Jun 30, 2025)
Jul 30, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 6, 2026 · 8-K — Current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Things to know before you trade REGN
- Last results release: Oct 6, 2026 (8-K Item 2.02). Previous ones: Jul 30, 2026, Jul 6, 2026, Apr 29, 2026. Based on that rhythm, the next report is likely around Jan 5, 2027 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.38% (largest 4.5%).
- Liquidity: about 800.18K shares (≈$637.22M) trade per day on average.
- 52-week position: $796.34 vs a range of $564.00–$859.34 (79% of the range).
- Dividends: last ex-dividend date Aug 18, 2026 ($0.94/share); 4 payments in the past 12 months.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Marion Mccourt sold 1,131 shares on Sep 3, 2026.
- Latest filings: 8-K Oct 6, 2026; 8-K Sep 30, 2026; 10-Q Jul 30, 2026.
- Share count: 93.96M shares outstanding (Jul 13, 2012), +5.0% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
REGN market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | 802.33 | 809.49 | 792.58 | 796.34 | 798.80K |
| Oct 14, 2026 | 758.16 | 781.84 | 755.21 | 778.36 | 878.40K |
| Oct 13, 2026 | 762.49 | 765.60 | 743.57 | 753.12 | 629.60K |
| Oct 12, 2026 | 748.67 | 768.66 | 744.96 | 762.81 | 618.20K |
| Oct 9, 2026 | 737.20 | 751.27 | 732.83 | 746.54 | 466.00K |
| Oct 8, 2026 | 742.12 | 744.50 | 723.65 | 739.57 | 500.30K |
| Oct 7, 2026 | 738.05 | 753.68 | 734.18 | 742.12 | 626.40K |
| Oct 6, 2026 | 734.61 | 740.51 | 727.16 | 738.72 | 615.10K |
| Oct 5, 2026 | 734.37 | 736.42 | 722.02 | 726.47 | 694.70K |
| Oct 2, 2026 | 740.50 | 742.50 | 729.20 | 735.20 | 613.90K |
| Oct 1, 2026 | 766.53 | 777.43 | 726.02 | 734.81 | 1.04M |
| Sep 30, 2026 | 749.84 | 763.72 | 742.94 | 758.27 | 872.40K |
| Sep 29, 2026 | 745.85 | 752.47 | 741.83 | 750.51 | 804.30K |
| Sep 28, 2026 | 778.09 | 780.95 | 750.00 | 752.25 | 1.15M |
| Sep 25, 2026 | 803.87 | 803.87 | 784.13 | 788.04 | 592.10K |
| Sep 24, 2026 | 801.59 | 807.21 | 789.39 | 796.02 | 602.60K |
| Sep 23, 2026 | 805.23 | 813.53 | 790.02 | 801.82 | 721.10K |
| Sep 22, 2026 | 802.48 | 811.66 | 791.31 | 803.90 | 600.20K |
| Sep 21, 2026 | 786.03 | 801.44 | 779.96 | 798.17 | 704.40K |
| Sep 18, 2026 | 787.34 | 794.73 | 779.65 | 784.85 | 2.47M |
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals (REGN) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in TARRYTOWN, NY. State of incorporation: NY. Fiscal year ends December 31. SEC CIK 872589.
REGN board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Michael S Brown | Director | Jan 6, 2026 |
| Bonnie L Bassler | Director | Jan 8, 2026 |
| N Anthony Coles | Director | Jan 6, 2026 |
| Joseph L Goldstein | Director | Jan 6, 2026 |
| Kathryn Guarini | Director | Sep 3, 2026 |
| Christine A Poon | Director | Jan 6, 2026 |
| Arthur F Ryan | Director | Jul 7, 2026 |
| Leonard S Schleifer | Bd. Co-Chair, President & CEO | Jan 5, 2026 |
| George L Sing | Director | Jan 6, 2026 |
| David P Schenkein | Director | Jan 6, 2026 |
| Craig B. Thompson | Director | Jan 6, 2026 |
| George Yancopoulos | Bd. Co-Chair, President & CSO | Jan 5, 2026 |
| Huda Y Zoghbi | Director | Aug 12, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Christopher R. Fenimore | EVP Finance CFO | Aug 20, 2026 |
| Joseph J Larosa | EVP General Counsel and Secret | Aug 21, 2026 |
| Andrew J Murphy | EVP Research | Dec 11, 2025 |
| Marion Mccourt | EVP Commercial | Sep 3, 2026 |
| Jason Pitofsky | SVP Controller | Feb 11, 2026 |
| Leonard S Schleifer | Bd. Co-Chair, President & CEO | Jan 5, 2026 |
| Plew Daniel P Van | EVP & General Mgr, Industrial | Dec 11, 2025 |
| George Yancopoulos | Bd. Co-Chair, President & CSO | Jan 5, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 3, 2026 | Marion Mccourt | Sale | 1,131 | $857.39 |
| Sep 2, 2026 | Marion Mccourt | Sale | 1,215 | $850.00 |
| Sep 2, 2026 | Kathryn Guarini | Sale | 400 | $850.00 |
| Aug 10, 2026 | Kathryn Guarini | Sale | 400 | $800.00 |
| Aug 10, 2026 | Huda Y Zoghbi | Sale | 800 | $800.00 |
| Jul 2, 2026 | Arthur F Ryan | Sale | 200 | $650.15 |
| May 1, 2026 | Arthur F Ryan | Sale | 2 | $710.87 |
| May 1, 2026 | Arthur F Ryan | Sale | 5 | $711.49 |
| May 1, 2026 | Arthur F Ryan | Sale | 1 | $712.09 |
| May 1, 2026 | Arthur F Ryan | Sale | 2 | $714.13 |
| May 1, 2026 | Arthur F Ryan | Sale | 4 | $707.40 |
| May 1, 2026 | Arthur F Ryan | Sale | 6 | $709.45 |
| May 1, 2026 | Arthur F Ryan | Sale | 7 | $706.74 |
| May 1, 2026 | Arthur F Ryan | Sale | 14 | $705.56 |
| May 1, 2026 | Arthur F Ryan | Sale | 15 | $704.28 |
REGN financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $14.34B | $4.50B | 41.48 | $4.98B |
| Dec 31, 2024 | $14.20B | $4.41B | 38.34 | $4.42B |
| Dec 31, 2023 | $13.12B | $3.95B | 34.77 | $4.59B |
| Dec 31, 2022 | $12.17B | $4.34B | 38.22 | $5.01B |
| Dec 31, 2021 | $16.07B | $8.08B | 71.97 | $7.08B |
Latest balance sheet: total assets $41.73B, total liabilities $10.02B, cash $2.46B (as of Jun 30, 2026).
REGN earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Oct 6, 2026 | 8-K Item 2.02 (results) | $738.72 |
| Jul 30, 2026 | 8-K Item 2.02 (results) | $738.34 |
| Jul 6, 2026 | 8-K Item 2.02 (results) | $649.81 |
| Apr 29, 2026 | 8-K Item 2.02 (results) | $686.36 |
| Apr 8, 2026 | 8-K Item 2.02 (results) | $775.53 |
| Jan 30, 2026 | 8-K Item 2.02 (results) | $741.45 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $768.00 |
| Oct 28, 2025 | 8-K Item 2.02 (results) | $654.48 |
| Oct 6, 2025 | 8-K Item 2.02 (results) | $585.48 |
| Aug 1, 2025 | 8-K Item 2.02 (results) | $558.87 |
| Apr 29, 2025 | 8-K Item 2.02 (results) | $568.91 |
| Feb 4, 2025 | 8-K Item 2.02 (results) | $697.05 |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)AbbVie (ABBV)Merck (MRK)Abbott Laboratories (ABT)Vertex Pharmaceuticals Inc / Ma (VRTX)Pfizer (PFE)Bristol Myers Squibb (BMY)Astrazeneca (AZN)Novo Nordisk A S (NVO)
Popular today
Micron Technology (MU)Spdr S&P 500 Etf (SPY)Nvidia (NVDA)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Intel (INTC)Apple (AAPL)Microsoft (MSFT)Meta Platforms (META)Broadcom (AVGO)Tesla (TSLA)
More on REGN
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 15, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.